A spontaneous antibody response to NY-ESO-1 antigen has been shown to predict both CD8 and CD4 T cell response to NY-ESO-1.[17], [41] This will imply a possible clinical benefit given that CD8 T cells are critical in tumor rejection.[42] The other ramification of these results is the possibility of utilizing an NY-ESO-1 vaccine strategy in patients with TNBC to boost any preexisting immunity to NY-ESO-1. The gene discussed is CD8A; the disease is neoplasm.